These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 6116757

  • 1. Animal modelling of human polymorphic drug oxidation--the metabolism of debrisoquine and phenacetin in rat inbred strains.
    Al-Dabbagh SG, Idle JR, Smith RL.
    J Pharm Pharmacol; 1981 Mar; 33(3):161-4. PubMed ID: 6116757
    [Abstract] [Full Text] [Related]

  • 2. Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.
    Veronese ME, McLean S.
    Eur J Clin Pharmacol; 1991 Mar; 40(6):547-52. PubMed ID: 1884734
    [Abstract] [Full Text] [Related]

  • 3. Methoxyphenamine metabolism in rat models of human debrisoquine phenotypes.
    Roy SD, Hawes EM, McKay G, Hubbard JW, Midha KK.
    Can J Physiol Pharmacol; 1985 Jul; 63(7):778-81. PubMed ID: 3876145
    [Abstract] [Full Text] [Related]

  • 4. In-vivo and in-vitro dextromethorphan metabolism in SD and DA rat. An animal model of the debrisoquine-type polymorphic oxidation in man.
    Zysset T, Zeugin T, Küpfer A.
    Biochem Pharmacol; 1988 Aug 15; 37(16):3155-60. PubMed ID: 3401246
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism.
    Muralidharan G, Midha KK, McKay G, Hawes EM, Inaba T.
    Xenobiotica; 1989 Feb 15; 19(2):189-97. PubMed ID: 2786289
    [Abstract] [Full Text] [Related]

  • 8. The contribution of genetically determined oxidation status to inter-individual variation in phenacetin disposition.
    Devonshire HW, Kong I, Cooper M, Sloan TP, Idle JR, Smith RL.
    Br J Clin Pharmacol; 1983 Aug 15; 16(2):157-66. PubMed ID: 6615690
    [Abstract] [Full Text] [Related]

  • 9. Antipyrine metabolism in female Lewis and Dark Agouti strains of rats, which are extensive and poor metabolizers of debrisoquine, respectively.
    Tanaka E, Kobayashi S, Uchida E, Oguchi K, Yasuhara H.
    Jpn J Pharmacol; 1989 Mar 15; 49(3):433-5. PubMed ID: 2747044
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Spectral binding studies of the polymorphically metabolized drugs debrisoquine, sparteine and phenformin by cytochrome P-450 of normal and hydroxylation deficient rat strains.
    Küpfer A, Al-Dabbagh SG, Ritchie JC, Idle JR, Smith RL.
    Biochem Pharmacol; 1982 Oct 15; 31(20):3193-9. PubMed ID: 7150348
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.
    Peart GF, Boutagy J, Shenfield GM.
    Eur J Clin Pharmacol; 1987 Oct 15; 33(4):397-402. PubMed ID: 3443146
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Metabolic oxidation of methaqualone in extensive and poor metabolisers of debrisoquine.
    Oram M, Wilson K, Burnett D, Al-Dabbagh SG, Idle JR, Smith RL.
    Eur J Clin Pharmacol; 1982 Oct 15; 23(2):147-50. PubMed ID: 7140803
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.